etidronate has been researched along with Cardiovascular Diseases in 5 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etidronate can increase bone mineralization in women with osteoporosis, but will it be useful for prophylaxis? Oestrogens can prevent bone loss, but is the increased risk of breast cancer sufficient to preclude their use? Do oestrogens increase or decrease the risk of cardiovascular disease? A combination of oestrogen and progesterone may avoid the increased risk of uterine cancer but what are the effects of long term administration? Do the potential benefits of hormone therapy justify the costs and treatment of large numbers of women who without therapy would never have developed complications attributable to oestrogen lack? (Herman J: Fam Phys 1990; 18: 39-40) Given these uncertainties, is postmenopausal administration of hormones reasonable or prudent? The current literature does not provide adequate answers to these questions." | 1.28 | Selections from current literature: hormone therapy in postmenopausal women. ( Froom, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, C | 1 |
| le Saux, O | 1 |
| Pomozi, V | 1 |
| Aherrahrou, R | 1 |
| Kriesen, R | 1 |
| Stölting, S | 1 |
| Liebers, A | 1 |
| Kessler, T | 1 |
| Schunkert, H | 1 |
| Erdmann, J | 1 |
| Aherrahrou, Z | 1 |
| Luckish, A | 1 |
| Cernes, R | 1 |
| Boaz, M | 1 |
| Gavish, D | 1 |
| Matas, Z | 1 |
| Fux, A | 1 |
| Shargorodsky, M | 1 |
| Ye, Y | 1 |
| Hu, SJ | 1 |
| Goldstein, MR | 1 |
| Froom, J | 1 |
1 trial available for etidronate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.
Topics: Aged; Arteries; Biomarkers; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; D | 2008 |
4 other studies available for etidronate and Cardiovascular Diseases
| Article | Year |
|---|---|
Etidronate prevents dystrophic cardiac calcification by inhibiting macrophage aggregation.
Topics: Animals; Bone Density Conservation Agents; Calcinosis; Cardiovascular Diseases; Cell Aggregation; Ce | 2018 |
Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Topics: Apolipoproteins; Arteries; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Et | 2009 |
Bisphosphonate therapy and vascular calcification.
Topics: Blood Vessels; Calcification, Physiologic; Calcinosis; Calcium Channel Blockers; Cardiovascular Dise | 2000 |
Selections from current literature: hormone therapy in postmenopausal women.
Topics: Calcium, Dietary; Cardiovascular Diseases; Estrogen Replacement Therapy; Etidronic Acid; Female; Hum | 1991 |